MiRNA-12129 Suppresses Cell Proliferation and Block Cell Cycle Progression by Targeting SIRT1 in GASTRIC Cancer.
MiRNA-12129
SIRT1
cell cycle progression
cell proliferation
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
5
1
2021
Statut:
ppublish
Résumé
Gastric cancer is the most commonly occurring cancer with a rapidly increasing incidence rate worldwide. The underlying molecular mechanisms of gastric cancer require further investigation. MicroRNAs exhibit tissue sensitivity as tumor biomarkers that play a role by promoting tumor growth as oncogenes or tumor suppressor genes. We evaluated the effects of microRNA-12129 on gastric cancer and identified the underlying mechanisms of microRNA-12129. Quantitative real-time polymerase chain reaction was conducted to determine the expression levels of microRNA-12129 and sirtuin 1
Identifiants
pubmed: 32508267
doi: 10.1177/1533033820928144
pmc: PMC7281879
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
SIRT1 protein, human
EC 3.5.1.-
Sirtuin 1
EC 3.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533033820928144Commentaires et corrections
Type : ExpressionOfConcernIn
Références
Onco Targets Ther. 2018 Dec 04;11:8695-8704
pubmed: 30584327
Biomed Pharmacother. 2019 Jul;115:108947
pubmed: 31078043
Front Endocrinol (Lausanne). 2018 Sep 24;9:569
pubmed: 30319549
Biomed Res Int. 2016;2016:8103019
pubmed: 27597973
Oncol Lett. 2018 Sep;16(3):3248-3254
pubmed: 30127921
Onco Targets Ther. 2019 Apr 18;12:2999-3009
pubmed: 31114243
Oncol Rep. 2018 Feb;39(2):695-702
pubmed: 29207181
BMC Cancer. 2019 Jun 13;19(1):577
pubmed: 31196010
Cancer Lett. 2017 Dec 28;411:1-11
pubmed: 28964787
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6442-9
pubmed: 26261520
PLoS One. 2013 Nov 21;8(11):e70627
pubmed: 24278101
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3270-3276
pubmed: 31081079
Onco Targets Ther. 2019 May 21;12:3965-3976
pubmed: 31190893
Int J Clin Exp Pathol. 2015 May 01;8(5):5224-9
pubmed: 26191221
Biomed Res Int. 2017;2017:5348490
pubmed: 29333444
Oncotarget. 2017 Feb 14;8(7):11071-11082
pubmed: 28052003
Biomed Res Int. 2016;2016:5083841
pubmed: 27493958
Breast Cancer Res. 2019 May 17;21(1):64
pubmed: 31101119
Cancer Manag Res. 2018 Feb 07;10:239-248
pubmed: 29445300
Toxins (Basel). 2018 Apr 19;10(4):
pubmed: 29671784
Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):415-421
pubmed: 26862948
Cancer Med. 2014 Dec;3(6):1553-61
pubmed: 25146318
Mol Cancer Res. 2013 Dec;11(12):1497-507
pubmed: 24107295
Onco Targets Ther. 2019 Jan 18;12:657-667
pubmed: 30705594
J Cell Physiol. 2019 Sep;234(9):15395-15406
pubmed: 30710340